

**Mental Health Medication Advisory Committee  
Meeting Agenda, Open Session  
May 10, 2016, 2:00-4:00pm**

**Meeting Location:** HP Enterprise Services, Capital Room, 6511 SE Forbes Ave, Topeka, KS 66619

**Committee Members:** Susan Mosier, MD, MBA, FACS (Chair), Vishal Adma, MD, MS, CMQ, CPE, Holly Cobb, ARNP, Nicole Ellermeier, PharmD, Bradley Grinage, MD, Rebecca Klingler, MD, Charles Millhuff, DO, Karen Moeller, PharmD, BCPP, Taylor Porter, MD

**KDHE Staff:** Aaron Dunkel, Deputy Secretary of KDHE/ Appointed Temporary MHMAC Chair, Liane Larson, PharmD, MPH, Carole Arace

**MCO Staff:** Jonalan Smith, PharmD, FASCP, Sosunmolu Shoyinka, MD, Jennifer Murff, RPh, John Esslinger, MD, MMM, Lisa Todd, RPh, BBA, William Mack, MD

I. Call to Order

- A. Introductions
- B. Announcements

II. Old Business

- A. Review and Approval of February 9, 2016 meeting minutes
- B. Prior Authorization Criteria

1. Use of Benzodiazepines and Buprenorphine Products – Review proposed clinical criteria for medication assisted treatment program patients prescribed benzodiazepines.

- a. Prior Authorization Criteria
- b. Clinical Public Comment \*
- c. Committee Discussion

2. Stimulants and other ADHD Agents Dosing Limits – Review proposed daily dose limits for patients prescribed stimulants and other ADHD agents.

- a. Prior Authorization Criteria
- b. Clinical Public Comment \*
- c. Committee Discussion

3. Use of Stimulants and other ADHD Agents in Adults – Review proposed clinical criteria for adults prescribed stimulants and other ADHD agents.

- a. Prior Authorization Criteria
- b. Clinical Public Comment \*
- c. Committee Discussion

4. Use of Stimulants and other ADHD agents in children – Review proposed clinical criteria for children prescribed stimulants and other ADHD agents.

- a. Prior Authorization Criteria
- b. Clinical Public Comment \*
- c. Committee Discussion

### III. New Business

#### A. Prior Authorization Criteria

1. Use of Multiple Concurrent Tricyclic Antidepressants (TCAs) – Review proposed clinical criteria for patients prescribed multiple tricyclic antidepressants.

- a. Prior Authorization Criteria
- b. Clinical Public Comment \*
- c. Committee Discussion

2. Use of Multiple Concurrent Mood Stabilizers– Review proposed clinical criteria for patients prescribed multiple mood stabilizers.

- a. Prior Authorization Criteria
- b. Clinical Public Comment \*
- c. Committee Discussion

3. Antipsychotic Dosing Limits for Children– Review proposed antipsychotic dosing limits for children.

- a. Prior Authorization Criteria
- b. Clinical Public Comment \*
- c. Committee Discussion

### IV. Process Improvement Initiatives - For informational purposes only

#### B. Preferred Prescriber Status

- 1. Committee Discussion

#### C. DUR approved criteria timeline

- 1. Committee Discussion

### V. Open Public Comment\*

### VI. Adjourn

**The next MHMAC meeting is scheduled for August 9, 2016.**

\* Clinical and open public comment requests and written testimony must be submitted 1 week prior to meeting to [llarson@kdheks.gov](mailto:llarson@kdheks.gov). If providing clinical comment, please indicate which agenda item you are requesting to comment on. Time limits during period of comment will be determined based on number of requests received.

**\*\*THIS AGENDA IS SUBJECT TO CHANGE\*\***